Partners from the Manchester University NHS Foundation Trust and the Manchester Science Partnerships launched its new APIS Assay Technologies business which will be dedicated to developing molecular diagnostic equipment to pinpoint unique treatments for individual patients and diseases.
Inspired by global biotechnology firm QIAGEN, APIS Assay Technologies was designed to address the growing number of health issues in Greater Manchester, and to pioneer research and development to support the booming and much-needed healthcare sector.
The collaboration between QIAGEN and Manchester’s many R&D hubs, which will also include the expansion of Health Innovation Manchester, is set to bring up to 1,500 medical-related jobs in the region to support the growing £6 billion industry.
Chair of Manchester Science Partnerships and of Health Innovation Manchester, Rowena Burns, said: “Greater Manchester’s vision is to create a globally-leading precision health campus for innovation, translational science and molecular diagnostics, employing up to 1,500 highly skilled people. Our partnership with QIAGEN underlines their role as the UK’s flagship industry partner and acts as a catalyst for Manchester to become a major hub for genomic research and industry in Europe.
“This is a major development for life sciences here – and across the North – and a testament to our long-standing history of forming public-private partnerships to support the creation of jobs, growth, address the health needs of local people, while also making an important international contribution to improved diagnosis and treatment of disease.”